Skip to main content

BMRN BioMarin Pharmaceutical Inc.

Healthcare

57.44 -1.07 -1.83% Close 11/2
Since 2024-12-02 -10.0%
Open
58.66
High
59.51
Low
57.17
Prev close
58.51
Volume
3.1M
Amplitude
4.00%
P/E
150.0
P/B
1.8
Revenue YoY (TTM)
+11.2%
52W 49.26 70.98

Is BioMarin Pharmaceutical Inc. a buy? Fundamentals and valuation first

As of 2026-10-30

Momentum: Good, Risk / liquidity: Good; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but TTM P/E is Expensive.
TTM P/E 150.03 95th percentile Expensive
Price / book 1.79 56th percentile Pricey
Free-cash-flow yield (%) 6.52 72th percentile Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Neutral FCF margin, TTM is Good, but ROE, TTM is Average.
ROE, TTM (%) 1.15 42th percentile Average
Operating margin, TTM (%) 8.02 52th percentile Good
FCF margin, TTM (%) 21.67 79th percentile Good
Quality Factor Investing: A US Quality Value Backtest
Growth Neutral Revenue growth, TTM YoY is Good, but Diluted EPS growth, TTM YoY is Average.
Revenue growth, TTM YoY (%) 11.2 63th percentile Good
Diluted EPS growth, TTM YoY (%) -88.43 24th percentile Average
Momentum Good All 2 indicators are Good.
60-day return (%) -4.8 55th percentile Good
240-day return (%) 6.91 60th percentile Good
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 140,751,290 90th percentile Top
60-day annualized volatility (%) 32.06 37th percentile Good
Factor Investing Explained: 10 Classic Factors in US Stocks

BioMarin Pharmaceutical Inc. (BMRN) today

1 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From BioMarin Pharmaceutical Inc. to every stock like it

AI finds several complementary traits of BioMarin Pharmaceutical Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. (BMRN) peers and tracking

Watchlist

This page refreshes daily after the close. Add BioMarin Pharmaceutical Inc. to your watchlist to track signal changes on your next visit.

BioMarin Pharmaceutical Inc. (BMRN) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Filed revenue acceleration

Active · now 11.2%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

13 historical occurrences (since 2018-08-03)

Average forward return after Filed revenue acceleration

20-day: Win 46.2%, Sample 13, Median -3.97%, Excess -4.1%, Beat mkt rate 38.5%

60-day: Win 15.4%, Sample 13, Median -7.26%, Excess -9.82%, Beat mkt rate 30.8%

120-day: Win 25%, Sample 12, Median -9.18%, Excess -15%, Beat mkt rate 25%

120 days after: historical avg -5.44%

20-day -2.51%
60-day -5.75%
120-day -5.44%
20-day
60-day
120-day
Win
46.2%
15.4%
25%
Sample
13
13
12
Median
-3.97%
-7.26%
-9.18%
Excess
-4.1%
-9.82%
-15%
Beat mkt rate
38.5%
30.8%
25%

Over 12 occurrences, 120-day forward avg declined 5.44%, lagged the market by 15 pts; win rate 25%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 76+8.9% +7.7% 86.8% -8.7%
20-40 422-19.9% -20.3% 4.5% -36.9%
40-60 94-9% -5.4% 8.5% -35.4%
60-80 You are here3Insufficient data
80-100 0Insufficient data

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 150.03, placing it in the 66.6 own-history percentile, inside the 60-80 bucket.

More history: Valuation × momentum analogs, Market-wide momentum baseline, Signals not active now

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
-9.7%
Win rate 33.1% Excess -19.8%
151d
-6%
Win rate 22.2% Excess -21%
81d
Insufficient data
(0d)
60-day momentum down
-6.4%
Win rate 30.5% Excess -14.2%
393d
Now
+3.1%
Win rate 61.1% Excess -9.1%
90d
Insufficient data
(0d)

Currently in “Middle × 60-day momentum down”: across 90 historical days, 120-day forward avg gained 3.1%, win rate 61.1%, lagged the market by 9.1%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

12 times historically; 60-day forward avg -3.11%, win rate 36.4%, beating the market by -3.13 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest

13 times historically; 60-day forward avg -7.22%, win rate 23.1%, beating the market by -4.21 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

34 times historically; 60-day forward avg -0.85%, win rate 35.5%, beating the market by -4.54 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.